Drug Trial Radar · NCT06544720
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
Last checked: Nov 19, 2026Latest source record: Aug 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Aug 2, 2023
Primary completion
Dec 31, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- The Affiliated Hospital of Qingdao UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Conditions
- Human Papillomavirus Associated Carcinomas
- Cervical Cancer
- Head and Neck Cancers
- Anal Cancer
- Vulva Cancer
- Vaginal Cancer
- Penile Cancer
- HPV-Related Malignancy
Interventions
SCG142 TCR-T cellsBiological
Monotherapy of SCG142
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The affiliated hosptial of qingdao university
Qingdao, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.